2006
DOI: 10.1016/j.ejphar.2006.04.005
|View full text |Cite
|
Sign up to set email alerts
|

Novel non-systemic inhibitor of ileal apical Na+-dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
27
0

Year Published

2007
2007
2019
2019

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 33 publications
(27 citation statements)
references
References 42 publications
0
27
0
Order By: Relevance
“…So far, a number of ASBT inhibitors having various structural characteristics have been synthesized. Among of them, three candidates-264W94, SC-435 and R-146224 ( Figure 1) were reported to block bile acid re-absorption and reduce cholesterol levels significantly in animal models [14][15][16]. In addition, it has recently been demonstrated in a Phase Ⅲ trial that A3309 (Figure 1), another ASBT inhibitor, can be used to treat patients with chronic idiopathic constipation (CIC).…”
Section: Introductionmentioning
confidence: 99%
“…So far, a number of ASBT inhibitors having various structural characteristics have been synthesized. Among of them, three candidates-264W94, SC-435 and R-146224 ( Figure 1) were reported to block bile acid re-absorption and reduce cholesterol levels significantly in animal models [14][15][16]. In addition, it has recently been demonstrated in a Phase Ⅲ trial that A3309 (Figure 1), another ASBT inhibitor, can be used to treat patients with chronic idiopathic constipation (CIC).…”
Section: Introductionmentioning
confidence: 99%
“…Current therapy of inhibiting bile acid absorption is based on sequestering them by using resins such as cholestyramine and colesevelam that bind bile acids in the intestinal lumen and prevent their absorption (33,34). However, poor patient compliance for cholestyramine and the need of high doses (several g/day) of bile acid sequestrants warrant the need for better and more efficient inhibitors of bile acid absorption (3,22). Therefore, further investigations are needed to delineate the modulation of bile acid absorption in diabetes mellitus at the molecular level.…”
mentioning
confidence: 99%
“…Once internalized, reclaimed bile acids are secreted into portal circulation via OST␣-OST␤ for return to the liver via the hepatic bile acid transporter, NTCP (1-3), thereby completing one cycle of enterohepatic circulation (4). Clinically, the intimate link between ASBT and cholesterol may be exploited via blockage of bile acid reuptake, resulting in reduced cholesterol levels (5)(6)(7)(8)(9); this establishes the pharmaceutical relevance of ASBT in treatment of hypercholesterolemia (1, 10 -14). Moreover, ASBT constitutes an attractive target for prodrug strategies aimed at increasing oral bioavailability of poorly absorbed drugs (15)(16)(17).…”
mentioning
confidence: 99%